Abstract 491P
Background
Furmonertinib (AST2818) is a novel, promising oral third-generation Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR sensitive mutations and T790M mutation, which has demonstrated efficacy in NSCLC in previous clinical trials. However, the efficacy and safety of furmonertinib as adjuvant therapy in patients ≥ 65 years old remain unclear.
Methods
Patients who underwent radical lung cancer surgery with EGFR mutations from two independent medical centers were enrolled and received furmonertinib 80mg daily. The adjuvant therapy time (6-36months) depended on patients’pathologic stage and physical conditions. The disease-free survival (DFS), safety and tolerability were evaluated.
Results
This study retrospectively analyzed 101 patients who were pathologically confirmed adenocarcinoma, EGFR mutation-positive (exon 19 deletion/L858R), stage IA2-IIIA NSCLC (60 females, 41 males, ranging in age from 43 to 86 years, with a median age of 65). Among them, 55 cases were ≥ 65 years old (median age 69 years, including 21 ≥ 70 years old), and 46 cases were<65 years old (median age 56.5 years old). All patients were followed at least 10 months, and 68 (67.3%) of them have been followed up for over 2 years, median follow-up time was 22 months. At data cutoff, all patients were alive, only 3 of them had metastasis (CNS, chest wall, and pancreas, respectively). The 2-year DFS rates for patients ≥ 65 years old and<65 years old were 96% and 97%, respectively (p=0.98). During therapy, 39 (38.6%) patients had treatment-related adverse events (TRAEs) of any grade. The most common TRAEs were rash (19/101, 18.8%), mouth ulcer (9/101, 8.9%) ,diarrhea (9/101, 8.9%) and transaminase elevation (5/101, 5.0%). Only 3 (3.0%) patients had TRAEs of grade 3 or higher and 1(1.4%) of them discontinued therapy. There was no significant difference in the incidence of TRAEs of any grade in patients aged ≥ 65 years and < 65 years (30.9% and 47.8%, p=0.08, respectively).
Conclusions
This is the first real-world study to demonstrate that furmonertinib has good efficacy and a tolerable safety profile in elderly patients (≥ 65 years) with completely resected stage I-III NSCLC harboring EGFR mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract